Capstan announces $175M oversubscribed Series B financing to support CPTX2309 to early clinical proof-of-concept in autoimmune disorders.

Capstan Therapeutics launched today with $165m in financing to build on the foundational insights of world-renowned leaders in mRNA and cell therapy.

Mariner is still a new name in the affordable market, but the Capstan is a fine fingerstyle-friendly performer. Construction details could be improved. Tuners look clunky. MusicRadar's got your back ...

Capstan’s initial focus is the development of in vivo chimeric antigen receptor, or CAR T, therapies. CAR T-drugs are currently made from a patient’s own T cells, which are engineered in a lab ...

Capstan Therapeutics has launched with $165 million for in vivo cell engineering to treat disease. The start-up’s technology is based on research from the University of Pennsylvania, with ...

Capstan is combining surgical robots with catheter-based technology to provide a less invasive option for open heart surgery. The US-based startup will initially target mitral valve replacement ...

SAN DIEGO, September 26, 2024--Capstan announced it will present preclinical data on lead in vivo chimeric antigen receptor (CAR)-T candidate, CPTX2309, at ACR Convergence 2024.

Going forward, Capstan aims to grow its engineering, clinical development and operations teams with an eye on preparing for the first human clinical trials of its own valve and delivery system.

Capstan Therapeutics, Inc. (“Capstan”), a clinical-stage biotechnology company dedicated to advancing in vivo reprogramming of cells through RNA delivery using targeted lipid nanoparticles ...